User login
Key clinical point: The combination of camrelizumab, apatinib, and eribulin demonstrated a favorable efficacy and a manageable safety profile in patients with heavily pretreated advanced triple negative breast cancer (TNBC).
Major finding: The objective response rate (ORR), disease control rate, and median progression-free survival in the overall cohort were 37.0% (95% CI 23.2%-52.5%), 87.0% (95% CI 73.7%-95.1%), and 8.1 months (95% CI 4.6-10.3 months), respectively, whereas the ORR in patients who progressed on previous treatment with checkpoint inhibitor + chemotherapy was 25.0% (95% CI 3.2%-65.1%). Grade 3/4 treatment-related adverse events occurred in 41.3% of patients.
Study details: Findings are from a multicenter, phase 2 study including 46 patients with pretreated advanced TNBC who received camrelizumab on day 1, apatinib daily, and eribulin on days 1 and 8 of a 21-day cycle.
Disclosures: This work was supported by grants from the Natural Science Foundation of China, Guangdong Science and Technology Department, and other sources. The authors declared no conflicts of interest.
Source: Liu J et al. Multicenter phase II trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun. 2022;13:3011 (May 31). Doi: 10.1038/s41467-022-30569-0
Key clinical point: The combination of camrelizumab, apatinib, and eribulin demonstrated a favorable efficacy and a manageable safety profile in patients with heavily pretreated advanced triple negative breast cancer (TNBC).
Major finding: The objective response rate (ORR), disease control rate, and median progression-free survival in the overall cohort were 37.0% (95% CI 23.2%-52.5%), 87.0% (95% CI 73.7%-95.1%), and 8.1 months (95% CI 4.6-10.3 months), respectively, whereas the ORR in patients who progressed on previous treatment with checkpoint inhibitor + chemotherapy was 25.0% (95% CI 3.2%-65.1%). Grade 3/4 treatment-related adverse events occurred in 41.3% of patients.
Study details: Findings are from a multicenter, phase 2 study including 46 patients with pretreated advanced TNBC who received camrelizumab on day 1, apatinib daily, and eribulin on days 1 and 8 of a 21-day cycle.
Disclosures: This work was supported by grants from the Natural Science Foundation of China, Guangdong Science and Technology Department, and other sources. The authors declared no conflicts of interest.
Source: Liu J et al. Multicenter phase II trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun. 2022;13:3011 (May 31). Doi: 10.1038/s41467-022-30569-0
Key clinical point: The combination of camrelizumab, apatinib, and eribulin demonstrated a favorable efficacy and a manageable safety profile in patients with heavily pretreated advanced triple negative breast cancer (TNBC).
Major finding: The objective response rate (ORR), disease control rate, and median progression-free survival in the overall cohort were 37.0% (95% CI 23.2%-52.5%), 87.0% (95% CI 73.7%-95.1%), and 8.1 months (95% CI 4.6-10.3 months), respectively, whereas the ORR in patients who progressed on previous treatment with checkpoint inhibitor + chemotherapy was 25.0% (95% CI 3.2%-65.1%). Grade 3/4 treatment-related adverse events occurred in 41.3% of patients.
Study details: Findings are from a multicenter, phase 2 study including 46 patients with pretreated advanced TNBC who received camrelizumab on day 1, apatinib daily, and eribulin on days 1 and 8 of a 21-day cycle.
Disclosures: This work was supported by grants from the Natural Science Foundation of China, Guangdong Science and Technology Department, and other sources. The authors declared no conflicts of interest.
Source: Liu J et al. Multicenter phase II trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun. 2022;13:3011 (May 31). Doi: 10.1038/s41467-022-30569-0